THYROCARE - Thyrocare Technologies Limited Share Price

In the Q4 FY '26 earnings conference call, Thyrocare Technologies Limited management provided a strong outlook focused on growth, quality improvement, and strategic expansion into specialties. Key forward-looking points include:

1. Growth Trajectory: Management expects a sustained revenue growth trajectory driven by franchise expansion and partnerships. In FY '26, revenue grew by 21% year-on-year, with intentions to maintain that momentum in FY '27 through an expected mid- to high-teens growth rate.

2. Franchise Expansion: Thyrocare added nearly 3,000 franchisees over the last four years, and aims to continue expanding this network, projecting a total of about 11,000 franchisees by the end of FY '27. The company maintains a target of onboarding approximately 500 new franchisees per quarter.

3. Specialty Testing: The company will enhance its diagnostic offerings by entering specialty tests, including genomic and allergy diagnostics. The management has committed INR 5-8 crores for operational expenditures to support this initiative, aiming to leverage lower prices for specialty tests to drive market penetration.

4. Operational Improvements: Thyrocare's sample turnaround time averaged 3.43 hours, and 97% of samples are processed in NABL-accredited labs. They achieved a Six Sigma level of quality with reduced complaints to 3.06 per million tests.

5. Market Opportunity: The specialty testing market is identified as a significant growth area, expected to account for approximately 15-20% of the overall pathology market, equating to a potential INR 7,000-10,000 crores market.

6. Financials: For Q4 FY '26, consolidated revenue was INR 224 crores, with a gross margin of 74.7%. Profit after tax stood at INR 48.7 crores, reflecting a 128% year-on-year growth.

Overall, management's outlook emphasizes the combination of franchise growth, expansion into specialty diagnostics, and continued operational improvements to secure a leadership position in the healthcare diagnostics market.

Major Questions and Answers from the Q&A Section of Thyrocare's Earnings Transcript (May 12, 2026)

Question 1: "How do you see Thyrocare growing over the next few quarters in diagnostic and preventive space? What are the main priorities on your table?"

Answer: Our key growth drivers include franchise expansion and partnerships, maintaining a CAGR of 25% over four years, reaching almost 11,000 franchisees by FY26's end. We also aim to capture opportunities in insurance and healthtech segments. Additionally, our investments in specialty tests, such as genomics and allergy testing, will play a crucial role in our growth trajectory over the next few years.

Question 2: "How will you balance spending on technology, new labs, and shareholder return while keeping costs under control?"

Answer: Our operating philosophy emphasizes margin preservation before expenditures. We invest in growth only after ensuring operating leverage from our business growth. While we are investing in genomics and specialty areas, we remain disciplined about our costs, ensuring margins are protected even as we expand.

Question 3: "Can you help us understand the reasons for the gross margin expansion?"

Answer: Margins have remained stable and are expected to be around 73-74%. The expansion results from effective negotiations with vendors and a significant increase in test volume, allowing us to leverage purchasing power. The Tanzania business has had minimal impact on margins, as it has yet to break even.

Question 4: "Is there any GLP-1 traction starting from this quarter? Can we expect 15% test volume growth in the coming year?"

Answer: This quarter, test volume grew significantly due to strategic investments, yielding a 29% increase. While we're optimistic about the growth, our future guidance for volume growth is mid- to high-teens for FY27, driven primarily by increased test volumes rather than significant price hikes.

Question 5: "What segments are you planning to enter with the backward integration into consumables and diagnostics?"

Answer: We have plans to officially announce our strategy by June or July regarding our entry into allied services as we have identified opportunities in segments where we are significant consumers. We're aiming to enhance our product offerings considerably.

Question 6: "What is the market opportunity for specialty testing in the next 2 to 3 years?"

Answer: The specialty testing market, estimated to be 15-20% of the overall INR50,000-60,000 crore pathology market, represents a potential opportunity of around INR7,000-10,000 crores. This significant untapped market presents ample growth opportunities for us.

Question 7: "How has your insurance business performed in the past year, and what are the growth expectations for next year?"

Answer: Our insurance business grew approximately 45% year-on-year, driven by pre-policy medical checkups and annual health checkups. Although it remains a nascent segment, we are optimistic about its potential growth as we continue to deepen our market presence.

Question 8: "What will be the EBITDA margins going forward? Will specialty segments affect margin expansion?"

Answer: Specialty segments will initially not contribute significantly to margin expansion. We expect EBITDA margins for FY27 to remain stable around 32-34%, with further operating leverage to support investment in growth while maintaining current margin levels.